Chicago, Periscope and PROactive: CV risk modification in diabetes with pioglitazone

Fundamental and Clinical Pharmacology

Volumn 23, Issue 6, 2009, Pages 675-679

  John Betteridge, D ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Chicago; Glycaemic control; Periscope; Pioglitazone; PROactive; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ATHEROMA; BIOASSAY; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG FATALITY; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 70449467324     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00741.x     Document Type: Review

References (22)

1. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352 837 853.
2. Statton I.M., Adler A.I., Neil H.A.W. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS: 35): prospective observational study. Brit. Med. J. (2000) 321 405 412.
3. Selvin E., Marinopoulos S., Berkenblit G. et al. Meta Analysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. (2004) 141 421 431.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. (2008) 358 2545 2559.
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. (2008) 358 2560 2572.
6. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycaemia in type 2 diabetes; a consensus algo-rhythm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2006) 49 1711 1721.
7. Holman R.R., Paul S.K., Bethel M.A., Mathews D.R., Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008) 359 1 13.
8. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356 2457 2471. (Pubitemid 46919772)
9. Goldfine A.B. Assessing the cardiovascular safety of diabetes therapies. N. Engl. J. Med. (2008) 359 1092 1095.
10. Dormandy J.A., Charbonnel B., Eckland D.J. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive trial (PRO-spective pioglitAzon Clinical Trial in macroVascular Events) a randomized controlled trial. Lancet (2005) 366 1279 1289.
11. Betteridge D.J., DeFronzo R.A., Chilton R.J. PROactive: time for a critical appraisal. Eur. Heart J. (2008) 29 969 983.
12. Erdmann E., Dormandy J.A., Charbonnel B. et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. J. Am. Coll. Cardiol. (2007) 49 1772 1780.
13. Wilcox R., Bousser M.-G., Betteridge D.J. et al. for the PROactive Investigators pioglitazone in patients with type2 diabetes with or without previous stroke. Results from PROactive (PROspective piogltAzone Clinical Trial In macroVascular Events). Stroke (2007) 38 865 873.
14. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet (2005) 366 1241 1242.
15. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet (2007) 370 1129 1136.
16. Erdmann E., Charbonnel B., Wilcox R. et al. Pioglitazone use and heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease. Data from the PROactive Study. Diabetes Care (2007) 30 2773 2778.
17. Erdmann E., Wilcox R. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur. Heart J. (2008) 29 12 20.
18. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events inpatients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 298 1180 1188.
19. Mazzone T., Meyer P.M., Feinstein S.B. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 296 2572 2581.
20. Nissen S.E., Nicholls S.J., Wolski K. et al. for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA (2008) 299 1561 1573.
21. Steg P.G., Marre M. Does PERISCOPE provide a new perspective on diabetic treatment? JAMA (2008) 299 1603 1604.
22. Davidson M., Meyer P.M., Haffner S. et al. Increased high density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes. Circulation (2008) 117 2123 2130.